Search

Your search keyword '"Garfall A"' showing total 655 results
Start Over Author "Garfall A"
655 results on '"Garfall A"'

2. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

Author

Ghilardi, Guido, Fraietta, Joseph A., Gerson, James N., Van Deerlin, Vivianna M., Morrissette, Jennifer J. D., Caponetti, Gabriel C., Paruzzo, Luca, Harris, Jaryse C., Chong, Elise A., Susanibar Adaniya, Sandra P., Svoboda, Jakub, Nasta, Sunita D., Ugwuanyi, Ositadimma H., Landsburg, Daniel J., Fardella, Eugenio, Waxman, Adam J., Chong, Emeline R., Patel, Vrutti, Pajarillo, Raymone, Kulikovskaya, Irina, Lieberman, David B., Cohen, Adam D., Levine, Bruce L., Stadtmauer, Edward A., Frey, Noelle V., Vogl, Dan T., Hexner, Elizabeth O., Barta, Stefan K., Porter, David L., Garfall, Alfred L., Schuster, Stephen J., June, Carl H., and Ruella, Marco

Published
2024
Full Text
View/download PDF

3. Teclistamab versus real-world physicians choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.

Author

Krishnan, Amrita, Nooka, Ajay, Chari, Ajai, Garfall, Alfred, Martin, Thomas, Nair, Sandhya, Lin, Xiwu, Qi, Keqin, Londhe, Anil, Pei, Lixia, Ammann, Eric, Kobos, Rachel, Smit, Jennifer, Parekh, Trilok, Marshall, Alexander, Slavcev, Mary, and Usmani, Saad

Subjects
B-cell maturation antigen, MajesTEC-1, bispecific antibody, comparative effectiveness, indirect treatment comparison, Humans, Multiple Myeloma, Treatment Outcome, Dexamethasone, Antineoplastic Agents, Physicians, Antineoplastic Combined Chemotherapy Protocols
Abstract

Aim: We compared the effectiveness of teclistamab versus real-world physicians choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC-1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting. Overall survival, progression-free survival and time to next treatment were compared. Results: After inverse probability of treatment weighting, baseline characteristics were similar between cohorts (teclistamab, n = 165; RWPC, n = 364 [766 observations]). Teclistamab treated patients had numerically better overall survival (hazard ratio [HR]: 0.82 [95% CI: 0.59-1.14]; p = 0.233) and significantly greater progression-free survival (HR: 0.43 [0.33-0.56]; p

Published
2023

4. Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel

Author

Guido Ghilardi, Luca Paruzzo, Vrutti Patel, Jakub Svoboda, Emeline R. Chong, Eugenio Fardella, Elise A. Chong, Giulia Gabrielli, Sunita D. Nasta, Daniel J. Landsburg, Jordan Carter, Raymone Pajarillo, Stefan K. Barta, Griffin White, Elizabeth Weber, Ellen Napier, David L. Porter, Alfred L. Garfall, Stephen J. Schuster, and Marco Ruella

Subjects
Non-Hodgkin lymphoma (NHL), Chimeric antigen receptor T cells (CART), Lymphodepletion, Bbendamustine, Ccytokine-release syndrome (CRS), Immune effector cell associated neurotoxicity syndrome (ICANS), Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T cell (CART) products tisagenlecleucel and axicabtagene ciloleucel, as well as the anti-BCMA CART products idecabtagene vicleucel and ciltacabtagene autoleucel. However, bendamustine as lymphodepletion prior to lisocabtagene maraleucel (liso-cel), a 4-1BB co-stimulated, fixed CD4:CD8 ratio anti-CD19 CART product, has not been described yet. Thus, we studied a cohort of sequentially-treated patients with large B-cell lymphomas who received bendamustine lymphodepletion before liso-cel at the University of Pennsylvania between 5/2021 and 12/2023 (n = 31). Patients were evaluated for toxicities and responses. Of note, 7 patients (22.6%) would have dnot met the inclusion criteria for the registrational liso-cel clinical trials, mostly due to older age. Overall and complete response rates were 76.9% and 73.1%, respectively. At a median follow-up of 6.3 months, the 6-month progression-free and overall survival were 59.9% and 91.1%, respectively. Rates of cytokine-release syndrome (CRS) and neurotoxicity (ICANS) of any grade were 9.7% and 9.7%, respectively, with no grade ≥ 3 events. No infections were reported during the first 30 days following liso-cel infusion. Neutropenia ≥ grade 3 was observed in 29.0% of patients; thrombocytopenia ≥ grade 3 occurred in 9.7%. In conclusion, bendamustine lymphodepletion before liso-cel appears to be a strategy that can drive tumor responses while ensuring a mild toxicity profile.

Published
2024
Full Text
View/download PDF

5. Teclistamab in Relapsed or Refractory Multiple Myeloma

Author

Moreau, Philippe, Garfall, Alfred L, van de Donk, Niels WCJ, Nahi, Hareth, San-Miguel, Jesús F, Oriol, Albert, Nooka, Ajay K, Martin, Thomas, Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Sidana, Surbhi, Delforge, Michel, Pei, Lixia, Trancucci, Danielle, Verona, Raluca, Girgis, Suzette, Lin, Shun XW, Olyslager, Yunsi, Jaffe, Mindy, Uhlar, Clarissa, Stephenson, Tara, Van Rampelbergh, Rian, Banerjee, Arnob, Goldberg, Jenna D, Kobos, Rachel, Krishnan, Amrita, and Usmani, Saad Z

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Clinical Research, Vaccine Related, Clinical Trials and Supportive Activities, Biotechnology, Rare Diseases, Hematology, 6.2 Cellular and gene therapies, Evaluation of treatments and therapeutic interventions, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, B-Cell Maturation Antigen, CD3 Complex, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, T-Lymphocytes, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundTeclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.MethodsIn this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better).ResultsAmong 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).ConclusionsTeclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).

Published
2022

7. Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1

Author

Miao, Xin, Wu, Liviawati S., Lin, Shun Xin Wang, Xu, Yan, Chen, Yang, Iwaki, Yuki, Kobos, Rachel, Stephenson, Tara, Kemmerer, Kristy, Uhlar, Clarissa M., Banerjee, Arnob, Goldberg, Jenna D., Trancucci, Danielle, Apte, Amit, Verona, Raluca, Pei, Lixia, Desai, Rachit, Hickey, Kathleen, Su, Yaming, Ouellet, Daniele, Samtani, Mahesh N., Guo, Yue, Garfall, Alfred L., Krishnan, Amrita, Usmani, Saad Z., Zhou, Honghui, and Girgis, Suzette

Published
2023
Full Text
View/download PDF

10. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

Author

Martin, Thomas G., Moreau, Philippe, Usmani, Saad Z., Garfall, Alfred, Mateos, María-Victoria, San-Miguel, Jesús F., Oriol, Albert, Nooka, Ajay K., Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Krishnan, Amrita, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Delforge, Michel, Trancucci, Danielle, Pei, Lixia, Kobos, Rachel, Fastenau, John, Gries, Katharine S., and van de Donk, Niels W.C.J.

Published
2024
Full Text
View/download PDF

11. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines

Author

Ghilardi, Guido, Paruzzo, Luca, Svoboda, Jakub, Chong, Elise A., Shestov, Alexander A., Chen, Linhui, Cohen, Ivan J., Gabrielli, Giulia, Nasta, Sunita D., Porazzi, Patrizia, Landsburg, Daniel J., Gerson, James N., Carter, Jordan, Barta, Stefan K., Yelton, Rebecca, Pajarillo, Raymone, Patel, Vrutti, White, Griffin, Ballard, Hatcher J., Weber, Elizabeth, Napier, Ellen, Chong, Emeline R., Fraietta, Joseph A., Garfall, Alfred L., Porter, David L., Milone, Michael C., O’Connor, Roderick, Schuster, Stephen J., and Ruella, Marco

Published
2024
Full Text
View/download PDF

13. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Author

Touzeau, Cyrille, Krishnan, Amrita Y., Moreau, Philippe, Perrot, Aurore, Usmani, Saad Z., Manier, Salomon, Cavo, Michele, Martinez Chamorro, Carmen, Nooka, Ajay K., Martin, Thomas G., Karlin, Lionel, Leleu, Xavier, Bahlis, Nizar J., Besemer, Britta, Pei, Lixia, Stein, Sarah, Wang Lin, Shun Xin, Trancucci, Danielle, Verona, Raluca I., Girgis, Suzette, Miao, Xin, Uhlar, Clarissa M., Chastain, Katherine, and Garfall, Alfred L.

Published
2024
Full Text
View/download PDF

15. Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells

Author

Landsburg, Daniel J., Nasta, Sunita D., Svoboda, Jakub, Gerson, James N., Schuster, Stephen J., Barta, Stefan K., Chong, Elise A., Difilippo, Heather, Weber, Elizabeth, Cunningham, Kathleen, Catania, Christopher, Garfall, Alfred L., Stadtmauer, Edward A., Frey, Noelle V., and Porter, David L.

Published
2023
Full Text
View/download PDF

16. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Author

Smith, Melody, Dai, Anqi, Ghilardi, Guido, Amelsberg, Kimberly V., Devlin, Sean M., Pajarillo, Raymone, Slingerland, John B., Beghi, Silvia, Herrera, Pamela S., Giardina, Paul, Clurman, Annelie, Dwomoh, Emmanuel, Armijo, Gabriel, Gomes, Antonio L. C., Littmann, Eric R., Schluter, Jonas, Fontana, Emily, Taur, Ying, Park, Jae H., Palomba, Maria Lia, Halton, Elizabeth, Ruiz, Josel, Jain, Tania, Pennisi, Martina, Afuye, Aishat Olaide, Perales, Miguel-Angel, Freyer, Craig W., Garfall, Alfred, Gier, Shannon, Nasta, Sunita, Landsburg, Daniel, Gerson, James, Svoboda, Jakub, Cross, Justin, Chong, Elise A., Giralt, Sergio, Gill, Saar I., Riviere, Isabelle, Porter, David L., Schuster, Stephen J., Sadelain, Michel, Frey, Noelle, Brentjens, Renier J., June, Carl H., Pamer, Eric G., Peled, Jonathan U., Facciabene, Andrea, van den Brink, Marcel R. M., and Ruella, Marco

Published
2023
Full Text
View/download PDF

17. P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY

Author

Manisha Bhutani, Alfred Garfall, Katarina Uttervall, Saad Z Usmani, Lionel Karlin, Lotfi Benboubker, Hareth Nahi, Jesús San Miguel, Danielle Trancucci, Keqin Qi, Tara Stephenson, Alfredo Perales-Puchalt, Katherine Chastain, and Ajai Chari

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

18. P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1

Author

Niels W.C.J. van de Donk, Alfred Garfall, Lotfi Benboubker, Katarina Uttervall, Kaz Groen, Laura Rosiñol Dachs, Caroline Hodin, Tara Stephenson, Danielle Trancucci, Alfredo Perales-Puchalt, Rachel Kobos, Arnob Banerjee, and Maria-Victoria Mateos

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

19. P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Author

Surbhi Sidana, Philippe Moreau, Alfred Garfall, Manisha Bhutani, Albert Oriol, Ajay Nooka, Tom Martin, Laura Rosiñol Dachs, Maria-Victoria Mateos, Nizar J Bahlis, Rakesh Popat, Britta Besemer, Joaquín Martinez-Lopez, Amrita Krishnan, Michel Delforge, Danielle Trancucci, Raluca Verona, Tara Stephenson, Katherine Chastain, and Niels W.C.J. van de Donk

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

20. Human IL-6 fosters long-term engraftment of patient derived disease-driving myeloma cells in immunodeficient mice

Author

Hasanali, Zainul S., primary, Garfall, Alfred L., additional, Burzenski, Lisa, additional, Shultz, Leonard D., additional, Tang, Yan, additional, Kadu, Siddhant, additional, Sheppard, Neil C., additional, Liu, Wei, additional, Dopkin, Derek, additional, Vogl, Dan T., additional, Cohen, Adam D., additional, Waxman, Adam J., additional, Susanibar-Adaniya, Sandra P., additional, Carroll, Martin, additional, Stadtmauer, Edward A., additional, and Allman, David, additional

Published
2024
Full Text
View/download PDF

21. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.

Author

Cornell, Robert, Ky, Bonnie, Weiss, Brendan, Dahm, Cherie, Gupta, Deepak, Du, Liping, Carver, Joseph, Cohen, Adam, Engelhardt, Brian, Garfall, Alfred, Goodman, Stacey, Harrell, Shelton, Kassim, Adetola, Jadhav, Trafina, Jagasia, Madan, Moslehi, Javid, OQuinn, Rupal, Savona, Michael, Slosky, David, Smith, Amanda, Stadtmauer, Edward, Vogl, Dan, Waxman, Adam, and Lenihan, Daniel

Subjects
Adult, Aged, Aged, 80 and over, Bortezomib, Cardiovascular Diseases, Disease-Free Survival, Electrocardiography, Female, Heart Diseases, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Molecular Targeted Therapy, Multiple Myeloma, Natriuretic Peptide, Brain, Neoplasm Recurrence, Local, Oligopeptides, Prospective Studies, Proteasome Inhibitors, Risk Factors, Time-to-Treatment, Treatment Outcome, Troponin I, Troponin T
Abstract

PURPOSE: Cardiovascular adverse events (CVAEs) can occur during proteasome inhibitor (PI) therapy. We conducted a prospective, observational, multi-institutional study to define risk factors and outcomes in patients with multiple myeloma (MM) receiving PIs. PATIENTS AND METHODS: Patients with relapsed MM initiating carfilzomib- or bortezomib-based therapy underwent baseline assessments and repeated assessments at regular intervals over 6 months, including cardiac biomarkers (troponin I or T, brain natriuretic peptide [BNP], and N-terminal proBNP), ECG, and echocardiography. Monitoring occurred over 18 months for development of CVAEs. RESULTS: Of 95 patients enrolled, 65 received carfilzomib and 30 received bortezomib, with median 25 months of follow-up. Sixty-four CVAEs occurred, with 55% grade 3 or greater in severity. CVAEs occurred in 51% of patients treated with carfilzomib and 17% of those treated with bortezomib (P = .002). Median time to first CVAE from treatment start was 31 days, and 86% occurred within the first 3 months. Patients receiving carfilzomib-based therapy with a baseline elevated BNP level higher than 100 pg/mL or N-terminal proBNP level higher than 125 pg/mL had increased risk for CVAE (odds ratio, 10.8; P < .001). Elevated natriuretic peptides occurring mid-first cycle of treatment with carfilzomib were associated with a substantially higher risk of CVAEs (odds ratio, 36.0; P < .001). Patients who experienced a CVAE had inferior progression-free survival (log-rank P = .01) and overall survival (log-rank P < .001). PI therapy was safely resumed in 89% of patients, although 41% required chemotherapy modifications. CONCLUSION: CVAEs are common during PI therapy for relapsed MM, especially with carfilzomib, particularly within the first 3 months of therapy. CVAEs were associated with worse overall outcomes, but usually, discontinuation of therapy was not required. Natriuretic peptides were highly predictive of CVAEs; however, validation of this finding is necessary before uniform incorporation into the routine management of patients receiving carfilzomib.

Published
2019

22. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas

Author

Ghilardi, G., Chong, E.A., Svoboda, J., Wohlfarth, P., Nasta, S.D., Williamson, S., Landsburg, J.D., Gerson, J.N., Barta, S.K., Pajarillo, R., Myers, J., Chen, A.I., Schachter, L., Yelton, R., Ballard, H.J., Hodges Dwinal, A., Gier, S., Victoriano, D., Weber, E., Napier, E., Garfall, A., Porter, D.L., Jäger, U., Maziarz, R.T., Ruella, M., and Schuster, S.J.

Published
2022
Full Text
View/download PDF

24. Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma

Author

Amrita Krishnan, Ajay K Nooka, Ajai Chari, Alfred L Garfall, Thomas G Martin, Sandhya Nair, Xiwu Lin, Keqin Qi, Anil Londhe, Lixia Pei, Eric Ammann, Rachel Kobos, Jennifer Smit, Trilok Parekh, Alexander Marshall, Mary Slavcev, and Saad Z Usmani

Subjects
b-cell maturation antigen, bispecific antibody, comparative effectiveness, indirect treatment comparison, majestec-1, Public aspects of medicine, RA1-1270
Abstract

Aim: We compared the effectiveness of teclistamab versus real-world physician’s choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC- 1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting. Overall survival, progression-free survival and time to next treatment were compared. Results: After inverse probability of treatment weighting, baseline characteristics were similar between cohorts (teclistamab, n = 165; RWPC, n = 364 [766 observations]). Teclistamab treated patients had numerically better overall survival (hazard ratio [HR]: 0.82 [95% CI: 0.59– 1.14]; p = 0.233) and significantly greater progression-free survival (HR: 0.43 [0.33–0.56]; p < 0.0001) and time to next treatment (HR: 0.36 [0.27–0.49]; p < 0.0001) versus the RWPC cohort. Conclusion: Teclistamab offered clinical benefit over RWPC in triple-class exposed relapsed/refractory multiple myeloma.

Published
2023
Full Text
View/download PDF

25. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

Author

Dhakal, Binod, Shah, Nina, Kansagra, Ankit, Kumar, Ambuj, Lonial, Sagar, Garfall, Alfred, Cowan, Andrew, Poudyal, Bishesh Sharma, Costello, Caitlin, Gay, Francesca, Cook, Gordon, Quach, Hang, Einsele, Herman, Schriber, Jeff, Hou, Jian, Costa, Luciano, Aljurf, Mahmoud, Chaudhry, Maria, Beksac, Meral, Prince, Miles, Mohty, Mohamad, Janakiram, Murali, Callander, Natalie, Biran, Noa, Malhotra, Pankaj, Otero, Paula Rodriguez, Moreau, Philippe, Abonour, Rafat, Iftikhar, Raheel, Silberman, Rebecca, Mailankody, Sham, Gregory, Tara, Lin, Yi, Carpenter, Paul, Hamadani, Mehdi, Usmani, Saad, and Kumar, Shaji

Published
2022
Full Text
View/download PDF

26. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Author

Smith, Melody, Dai, Anqi, Ghilardi, Guido, Amelsberg, Kimberly V., Devlin, Sean M., Pajarillo, Raymone, Slingerland, John B., Beghi, Silvia, Herrera, Pamela S., Giardina, Paul, Clurman, Annelie, Dwomoh, Emmanuel, Armijo, Gabriel, Gomes, Antonio L. C., Littmann, Eric R., Schluter, Jonas, Fontana, Emily, Taur, Ying, Park, Jae H., Palomba, Maria Lia, Halton, Elizabeth, Ruiz, Josel, Jain, Tania, Pennisi, Martina, Afuye, Aishat Olaide, Perales, Miguel-Angel, Freyer, Craig W., Garfall, Alfred, Gier, Shannon, Nasta, Sunita, Landsburg, Daniel, Gerson, James, Svoboda, Jakub, Cross, Justin, Chong, Elise A., Giralt, Sergio, Gill, Saar I., Riviere, Isabelle, Porter, David L., Schuster, Stephen J., Sadelain, Michel, Frey, Noelle, Brentjens, Renier J., June, Carl H., Pamer, Eric G., Peled, Jonathan U., Facciabene, Andrea, van den Brink, Marcel R. M., and Ruella, Marco

Published
2022
Full Text
View/download PDF

27. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma

Author

Qazilbash, Muzaffar H., Saini, Neeraj Y., Cha, Soung-chul, Wang, Zhe, Stadtmauer, Edward A., Baladandayuthapani, Veerabhadran, Lin, Heather, Tross, Beryl, Honhar, Medhavi, Rao, Sheetal S., Kim, Kunhwa, Popescu, Michael, Szymura, Szymon, Zhang, Tiantian, Anderson, Aaron, Bashir, Qaiser, Shpall, Elizabeth J., Orlowski, Robert Z., Levine, Bruce L., Kerr, Naseem, Garfall, Alfred, Cohen, Adam, Vogl, Dan T., Dengel, Karen, June, Carl H., Champlin, Richard, and Kwak, Larry W.

Published
2022
Full Text
View/download PDF

28. Implementation of an Approach to Equitable Allocation of SARS-CoV-2 Monoclonal Antibodies for Preexposure Prophylaxis: Experience From a Single Medical Center.

Author

Hamilton, Keith W, Hua, Elvis, Dutcher, Lauren, Lynch, Holly Fernandez, Junker, Paul, Doucette, Abigail G, Werner, Danielle, Kannel, Ethan Z, Civitello, Thomas, Gabriel, Peter, Ahya, Vivek N, Jacobs, Dina A, Garfall, Alfred, Pratz, Keith, Degnan, Kathleen O, Blumberg, Emily A, Capozzi, Donna, Craig, Ethan, Takach, Patricia, and Payne, Aimee S

Subjects
COVID-19 pandemic, HEALTH facilities, HEALTH equity, RACIAL differences, SOCIOECONOMIC status
Abstract

Background During the COVID-19 pandemic, SARS-CoV-2 monoclonal antibodies for preexposure prophylaxis (SMA-PrEP) offered patients who were immunocompromised another option for protection. However, SMA-PrEP posed administrative, operational, and ethical challenges for health care facilities, resulting in few patients receiving them. Although the first SMA-PrEP medication, tixagevimab and cilgavimab, had its authorization revoked due to compromised in vitro efficacy, new SMA-PrEP medications are currently completing clinical trials. This article provides an operational framework for administrative organization, patient identification and prioritization, equitable medication allocation, medication ordering and administration, and patient tracking. Methods A retrospective cohort study evaluating our hospital's SMA-PrEP administration strategy was performed. Multivariable logistic regression was used to examine factors associated with receipt of SMA-PrEP. Results Despite the barriers in administering this medication and the scarcity of resources, our hospital was able to administer at least 1 dose of SMA-PrEP to 1359 of 5902 (23.0%) eligible patients. Even with the steps taken to promote equitable allocation, multivariable logistic regression demonstrated that there were still differences by race, ethnicity, and socioeconomic status. As compared with patients who identified as Black, patients who identified as White (odds ratio [OR], 1.85; 95% CI, 1.46–2.33), Asian (OR, 1.59; 95% CI, 1.03–2.46), and Hispanic (OR, 1.53; 95% CI, 1.02–2.44) were more likely to receive SMA-PrEP. When compared with patients with low socioeconomic status, patients with high socioeconomic status (OR, 1.37; 95% CI, 1.05–1.78) were more likely to be allocated SMA-PrEP. Conclusions Despite efforts to mitigate health care disparities, differences by race/ethnicity and socioeconomic status still arose in patients receiving SMA-PrEP. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. CAR T-Cell Immunotherapy in Minority Patients with Lymphoma

Author

Ghilardi, Guido, primary, Williamson, Staci, additional, Pajarillo, Raymone, additional, Paruzzo, Luca, additional, Chen, Linhui, additional, Grady, Connor, additional, Doucette, Abigail, additional, Nemecek, Eneida, additional, Gabrielli, Giulia, additional, Barta, Stefan K., additional, Svoboda, Jakub, additional, Chong, Elise A., additional, Yelton, Rebecca, additional, Nasta, Sunita D., additional, Landsburg, Daniel J., additional, Ugwuanyi, Ositadimma, additional, Chen, Andy I., additional, Schachter, Levanto, additional, White, Griffin, additional, Ballard, Hatcher J., additional, Weber, Elizabeth, additional, Curley, Cara, additional, Porter, David L., additional, Garfall, Alfred L., additional, Hwang, Wei-Ting, additional, Guerra, Carmen E., additional, Maziarz, Richard T., additional, Schuster, Stephen J., additional, and Ruella, Marco, additional

Published
2024
Full Text
View/download PDF

30. Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma

Author

Chong, Elise A., primary, Chong, Emeline R., additional, Therwhanger, Dylan, additional, Nasta, Sunita D., additional, Landsburg, Daniel J., additional, Barta, Stefan K., additional, Svoboda, Jakub, additional, Gerson, James N., additional, Ghilardi, Guido, additional, Paruzzo, Luca, additional, Fraietta, Joseph A., additional, Weber, Elizabeth, additional, Stefano, Natalie, additional, Porter, David L., additional, Frey, Noelle V., additional, Garfall, Alfred L., additional, Ruella, Marco, additional, and Schuster, Stephen J., additional

Published
2024
Full Text
View/download PDF

31. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Author

Usmani, Saad Z, Garfall, Alfred L, van de Donk, Niels W C J, Nahi, Hareth, San-Miguel, Jesus F, Oriol, Albert, Rosinol, Laura, Chari, Ajai, Bhutani, Manisha, Karlin, Lionel, Benboubker, Lotfi, Pei, Lixia, Verona, Raluca, Girgis, Suzette, Stephenson, Tara, Elsayed, Yusri, Infante, Jeffrey, Goldberg, Jenna D, Banerjee, Arnob, Mateos, María-Victoria, and Krishnan, Amrita

Published
2021
Full Text
View/download PDF

32. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

Author

Bange, Erin M., Han, Nicholas A., Wileyto, Paul, Kim, Justin Y., Gouma, Sigrid, Robinson, James, Greenplate, Allison R., Hwee, Madeline A., Porterfield, Florence, Owoyemi, Olutosin, Naik, Karan, Zheng, Cathy, Galantino, Michael, Weisman, Ariel R., Ittner, Caroline A. G., Kugler, Emily M., Baxter, Amy E., Oniyide, Olutwatosin, Agyekum, Roseline S., Dunn, Thomas G., Jones, Tiffanie K., Giannini, Heather M., Weirick, Madison E., McAllister, Christopher M., Babady, N. Esther, Kumar, Anita, Widman, Adam J., DeWolf, Susan, Boutemine, Sawsan R., Roberts, Charlotte, Budzik, Krista R., Tollett, Susan, Wright, Carla, Perloff, Tara, Sun, Lova, Mathew, Divij, Giles, Josephine R., Oldridge, Derek A., Wu, Jennifer E., Alanio, Cécile, Adamski, Sharon, Garfall, Alfred L., Vella, Laura A., Kerr, Samuel J., Cohen, Justine V., Oyer, Randall A., Massa, Ryan, Maillard, Ivan P., Maxwell, Kara N., Reilly, John P., Maslak, Peter G., Vonderheide, Robert H., Wolchok, Jedd D., Hensley, Scott E., Wherry, E. John, Meyer, Nuala J., DeMichele, Angela M., Vardhana, Santosha A., Mamtani, Ronac, and Huang, Alexander C.

Published
2021
Full Text
View/download PDF

33. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Author

Kumar, Shaji K., primary, Callander, Natalie S., additional, Adekola, Kehinde, additional, Anderson, Larry D., additional, Baljevic, Muhamed, additional, Baz, Rachid, additional, Campagnaro, Erica, additional, Castillo, Jorge J., additional, Costello, Caitlin, additional, D’Angelo, Christopher, additional, Derman, Benjamin, additional, Devarakonda, Srinivas, additional, Elsedawy, Noura, additional, Garfall, Alfred, additional, Godby, Kelly, additional, Hillengass, Jens, additional, Holmberg, Leona, additional, Htut, Myo, additional, Huff, Carol Ann, additional, Hultcrantz, Malin, additional, Kang, Yubin, additional, Larson, Sarah, additional, Lee, Hans, additional, Liedtke, Michaela, additional, Martin, Thomas, additional, Omel, James, additional, Robinson, Timothy, additional, Rosenberg, Aaron, additional, Sborov, Douglas, additional, Schroeder, Mark A., additional, Sherbenou, Daniel, additional, Suvannasankha, Attaya, additional, Valent, Jason, additional, Varshavsky-Yanovsky, Asya Nina, additional, Snedeker, Jenna, additional, and Kumar, Rashmi, additional

Published
2024
Full Text
View/download PDF

34. Bendamustine Lymphodepletion Before Axicabtagene Ciloleucel Is Safe and Associates with Reduced Inflammatory Cytokines

Author

Ghilardi, Guido, primary, Paruzzo, Luca, additional, Svoboda, Jakub, additional, Chong, Elise A., additional, Shestov, Alexander A, additional, Chen, Linhui, additional, Cohen, Ivan J, additional, Gabrielli, Giulia, additional, Nasta, Sunita D., additional, Porazzi, Patrizia, additional, Landsburg, Daniel J., additional, Gerson, James N., additional, Carter, Jordan, additional, Barta, Stefan K., additional, Yelton, Rebecca Dawn, additional, Pajarillo, Raymone, additional, Patel, Vrutti, additional, White, Griffin, additional, Ballard, Hatcher, additional, Weber, Elizabeth, additional, Napier, Ellen B, additional, Chong, Emeline R, additional, Fraietta, Joseph A., additional, Garfall, Alfred, additional, Porter, David L., additional, Milone, Michael C, additional, O'Connor, Roddy S, additional, Schuster, Stephen J., additional, and Ruella, Marco, additional

Published
2023
Full Text
View/download PDF

36. P20 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Vs Belantamab Mafodotin for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Moreau, P., primary, Usmani, S.Z., additional, van de Donk, N.W.C.J., additional, Garfall, A.L., additional, Delforge, M., additional, Oriol, A., additional, Nooka, A., additional, Rosiñol, L., additional, Bahlis, N., additional, Rodriguez Otero, P., additional, Martin, T.G., additional, Diels, J., additional, Van Sanden, S., additional, Pei, L., additional, Ammann, E., additional, Chastain, K., additional, Marshall, A., additional, Slavcev, M., additional, Londhe, A., additional, and Krishnan, A., additional

Published
2023
Full Text
View/download PDF

37. CO129 Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy (RWPC) for Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Krishnan, A., primary, Nooka, A., additional, Chari, A., additional, Garfall, A.L., additional, Martin, T., additional, Nair, S., additional, Lin, X., additional, Qi, K., additional, Londhe, A., additional, Pei, L., additional, Ammann, E., additional, Chastain, K., additional, Parekh, T., additional, Marshall, A., additional, Slavcev, M., additional, and Usmani, S.Z., additional

Published
2023
Full Text
View/download PDF

38. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Author

Kumar, Shaji K., primary, Callander, Natalie S., additional, Adekola, Kehinde, additional, Anderson, Larry D., additional, Baljevic, Muhamed, additional, Baz, Rachid, additional, Campagnaro, Erica, additional, Castillo, Jorge J., additional, Costello, Caitlin, additional, D’Angelo, Christopher, additional, Devarakonda, Srinivas, additional, Elsedawy, Noura, additional, Garfall, Alfred, additional, Godby, Kelly, additional, Hillengass, Jens, additional, Holmberg, Leona, additional, Htut, Myo, additional, Huff, Carol Ann, additional, Hultcrantz, Malin, additional, Kang, Yubin, additional, Larson, Sarah, additional, Lee, Hans C., additional, Liedtke, Michaela, additional, Martin, Thomas, additional, Omel, James, additional, Robinson, Timothy, additional, Rosenberg, Aaron, additional, Sborov, Douglas, additional, Schroeder, Mark A., additional, Sherbenou, Daniel, additional, Suvannasankha, Attaya, additional, Valent, Jason, additional, Varshavsky-Yanovsky, Asya Nina, additional, Kumar, Rashmi, additional, and Snedeker, Jenna, additional

Published
2023
Full Text
View/download PDF

39. Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies

Author

Zhang, Zheng, primary, Markmann, Caroline, additional, Yu, Ming, additional, Agarwal, Divyansh, additional, Rostami, Susan, additional, Wang, Wei, additional, Liu, Chengyang, additional, Zhao, Huiwu, additional, Ochoa, Trini, additional, Parvathaneni, Kalpana, additional, Xu, Xiaoming, additional, Li, Eric, additional, Gonzalez, Vanessa, additional, Khadka, Roman, additional, Hoffmann, Jennifer, additional, Knox, James J., additional, Scholler, John, additional, Marcellus, Brooke, additional, Allman, David, additional, Fraietta, Joseph A., additional, Samelson-Jones, Benjamin, additional, Milone, Michael C., additional, Monos, Dimitri, additional, Garfall, Alfred L., additional, Naji, Ali, additional, and Bhoj, Vijay G., additional

Published
2023
Full Text
View/download PDF

40. CO93 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Versus Selinexor-Dexamethasone for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Moreau, P., primary, Usmani, S.Z., additional, van de Donk, N.W.C.J., additional, Garfall, A.L., additional, Delforge, M., additional, Oriol, A., additional, Nooka, A., additional, Rosiñol, L., additional, Bahlis, N., additional, Rodríguez Otero, P., additional, Martin, T., additional, Diels, J., additional, Van Sanden, S., additional, Pei, L., additional, Ammann, E., additional, Chastain, K., additional, Marshall, A., additional, Slavcev, M., additional, Londhe, A., additional, and Krishnan, A., additional

Published
2023
Full Text
View/download PDF

41. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

Author

Uy, GL, Costa, LJ, Hari, PN, Zhang, M-J, Huang, J-X, Anderson, KC, Bredeson, CN, Callander, NS, Cornell, RF, Perez, MAD, Dispenzieri, A, Freytes, CO, Gale, RP, Garfall, A, Gertz, MA, Gibson, J, Hamadani, M, Lazarus, HM, Kalaycio, ME, Kamble, RT, Kharfan-Dabaja, MA, Krishnan, AY, Kumar, SK, Kyle, RA, Landau, HJ, Lee, CH, Maiolino, A, Marks, DI, Mark, TM, Munker, R, Nishihori, T, Olsson, RF, Ramanathan, M, Rodriguez, TE, Saad, AA, Savani, BN, Schiller, GJ, Schouten, HC, Schriber, JR, Scott, E, Seo, S, Sharma, M, Ganguly, S, Stadtmauer, EA, Tay, J, To, LB, Vesole, DH, Vogl, DT, Wagner, JL, Wirk, B, Wood, WA, and D'Souza, A

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Rare Diseases, Stem Cell Research - Nonembryonic - Human, Cancer, Hematology, Clinical Research, Stem Cell Research, Transplantation, Regenerative Medicine, Adolescent, Adult, Aged, Autografts, Disease-Free Survival, Female, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cell Transplantation, Humans, Leukocyte Count, Male, Middle Aged, Multiple Myeloma, Platelet Count, Prospective Studies, Recovery of Function, Survival Rate, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (⩾0.5 × 10(9)/L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (⩾20 × 10(9)/L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.

Published
2015

42. S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN COMBINATION WITH DARATUMUMAB

Author

N. W. van de Donk, N. Bahlis, M.-V. Mateos, K. Weisel, B. Dholaria, A. L. Garfall, H. Goldschmidt, T. G. Martin, D. Morillo, D. E. Reece, D. Hurd, P. Rodríguez-Otero, M. Bhutani, A. D’Souza, A. Oriol, E. Askari, J. F. San-Miguel, K. M. Kortüm, D. Vishwamitra, S. Xin Wang Lin, T. J. Prior, L. Vandenberk, M.-A. D. Smit, J. D. Goldberg, R. Wäsch, and A. Chari

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

43. S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS

Author

C. Touzeau, A. Krishnan, P. Moreau, A. Perrot, S. Z. Usmani, S. Manier, M. Cavo, C. Martinez-Chamorro, A. Nooka, T. Martin, L. Karlin, X. Leleu, N. Bahlis, B. Besemer, L. Pei, R. Verona, S. Girgis, C. Uhlar, R. Kobos, and A. Garfall

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

44. P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON

Author

M. Delforge, S. Z. Usmani, N. W. van de Donk, A. L. Garfall, P. Moreau, A. Oriol, A. K. Nooka, L. Rosinol, N. Bahlis, P. Rodriguez-Otero, T. Martin, J. Diels, S. Van Sanden, L. Pei, E. Ammann, R. Kobos, M. Slavcev, J. Smit, A. Londhe, and A. Krishnan

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

45. P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1

Author

J. Martínez-López, P. Moreau, S. Z. Usmani, A. Garfall, N. W. van de Donk, J. F. San-Miguel, A. Oriol, A. Chari, L. Karlin, M.-V. Mateos, R. Popat, A. K. Nooka, S. Sidana, D. Trancucci, R. Verona, S. Girgis, C. Uhlar, T. Stephenson, A. Banerjee, and A. Krishnan

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

46. P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1

Author

R. Popat, P. Moreau, S. Z. Usmani, A. Garfall, M.-V. Mateos, J. F. San-Miguel, A. Oriol, A. K. Nooka, L. Rosinol, A. Chari, L. Karlin, A. Krishnan, N. Bahlis, T. Martin, B. Besemer, J. Martínez-López, M. Delforge, J. Fastenau, K. S. Gries, and N. W. van de Donk

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

48. PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON

Author

L. Rosinol, S. Z. Usmani, N. Bahlis, A. Y. Krishnan, A. K. Nooka, A. Oriol, M. Delforge, A. L. Garfall, N. W. van de Donk, P. Rodríguez Otero, T. G. Martin, J. Diels, S. Van Sanden, L. Pei, E. Ammann, R. Kobos, M. Slavcev, J. Smit, A. Londhe, and P. Moreau

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results